SPOTLIGHT: Genzyme wins Myozyme OK

Genzyme has won FDA approval to market Myozyme for Pompe disease, a regulatory win that could open the way to a billion dollars in annual revenue. Genzyme spent eight years and $500 million developing the drug for the rare condition. Report